SPRO
Spero Therapeutics Inc
$
2.410
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.450
Open
2.330
VWAP
2.39
Vol
586.69K
Mkt Cap
134.74M
Low
2.320
Amount
1.40M
EV/EBITDA(TTM)
--
Total Shares
53.99M
EV
83.62M
EV/OCF(TTM)
--
P/S(TTM)
2.90
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
0.00
-100%
--
--
0.00
-100%
--
--
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Spero Therapeutics, Inc. (SPRO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 231.45%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+231.45%
In Past 3 Month
1 Analyst Rating
107.47% Upside
Wall Street analysts forecast SPRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRO is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
107.47% Upside
Current: 2.410
Low
5.00
Averages
5.00
High
5.00
107.47% Upside
Current: 2.410
Low
5.00
Averages
5.00
High
5.00
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$5
2025-01-30
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$5
2025-01-30
Reiterates
Strong Buy
Reason
Evercore ISI Group
Josh Schimmer
Buy
to
Hold
Downgrades
$5
2024-12-20
Reason
Evercore ISI Group
Josh Schimmer
Price Target
$5
2024-12-20
Downgrades
Buy
to
Hold
Reason
Evercore ISI analyst Gavin Clark-Gartner downgraded Spero Therapeutics to In Line from Outperform with a $5 price target.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$5
2024-12-02
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$5
2024-12-02
Reiterates
Strong Buy
Reason
TD Cowen
Ritu Baral
Strong Buy
to
Hold
Downgrades
n/a
2024-11-18
Reason
TD Cowen
Ritu Baral
Price Target
n/a
2024-11-18
Downgrades
Strong Buy
to
Hold
Reason
TD Cowen analyst Ritu Baral downgraded Spero Therapeutics to Hold from Buy without a price target. The firm cites a lack of clarity on catalyst timing following discontinuation of the SPR720 Phase 2 program for the downgrade. TD now sees a lack of clarity on meaningful catalyst flow for the shares.
Cantor Fitzgerald
Louise Chen
Buy
Reiterates
n/a
2024-11-15
Reason
Cantor Fitzgerald
Louise Chen
Price Target
n/a
2024-11-15
Reiterates
Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$7 → $5
2024-11-04
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$7 → $5
2024-11-04
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Spero Therapeutics Inc (SPRO.O) is -3.12, compared to its 5-year average forward P/E of -2.66. For a more detailed relative valuation and DCF analysis to assess Spero Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.66
Current PE
-3.12
Overvalued PE
-0.80
Undervalued PE
-4.52
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.42
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.58
Undervalued EV/EBITDA
-3.43
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
12.67
Current PS
27.90
Overvalued PS
27.80
Undervalued PS
-2.45
Financials
Annual
Quarterly
FY2025Q1
YoY :
-36.61%
5.87M
Total Revenue
FY2025Q1
YoY :
+4.11%
-14.56M
Operating Profit
FY2025Q1
YoY :
+9.45%
-13.87M
Net Income after Tax
FY2025Q1
YoY :
+4.17%
-0.25
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
+72.67%
-236.06
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 1502.25% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
235.4K
USD
4
6-9
Months
0.0
USD
0
0-12
Months
14.7K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 1502.25% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
235.4K
USD
4
6-9
Months
0.0
USD
0
0-12
Months
14.7K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SPRO News & Events
Events Timeline
2025-05-28 (ET)
2025-05-28
07:17:32
GSK reports PIVOT-PO study for tebipenem HBr stopped early for efficacy
2025-05-28
07:05:59
Spero Therapeutics, GSK announce Phase 3 PIVOT-PO trial met primary endpoint
2025-04-28 (ET)
2025-04-28
16:08:20
Spero Therapeutics appoints Esther Rajavelu will serve as CEO
Sign Up For More Events
Sign Up For More Events
News
9.0
07-04NASDAQ.COMAZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
8.0
06-09BenzingaWall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
4.5
05-31BenzingaBenzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Sign Up For More News
People Also Watch
SPAI
Safe Pro Group Inc
3.850
USD
+2.94%
ESGL
ESGL Holdings Ltd
3.120
USD
+7.96%
DUOT
Duos Technologies Group Inc
7.920
USD
-1.61%
WWR
Westwater Resources Inc
0.899
USD
-8.27%
BHM
Bluerock Homes Trust Inc
13.910
USD
-0.64%
LOOP
Loop Industries Inc
1.230
USD
0.00%
LBGJ
Li Bang International Corporation Inc
1.360
USD
-3.55%
RFL
Rafael Holdings Inc
2.170
USD
+2.36%
UG
United-Guardian Inc
9.520
USD
+1.60%
ICCC
ImmuCell Corp
6.830
USD
+0.22%
FAQ
What is Spero Therapeutics Inc (SPRO) stock price today?
The current price of SPRO is 2.41 USD — it has increased 3.88 % in the last trading day.
What is Spero Therapeutics Inc (SPRO)'s business?
What is the price predicton of SPRO Stock?
What is Spero Therapeutics Inc (SPRO)'s revenue for the last quarter?
What is Spero Therapeutics Inc (SPRO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Spero Therapeutics Inc (SPRO)'s fundamentals?
How many employees does Spero Therapeutics Inc (SPRO). have?